Dermatology News

Pooled data from phase 2 and phase 3 studies suggest the efficacy and safety of Paratek Pharmaceuticals' investigational broad-spectrum antibiotic omadacycline is comparable to Zyvox in the treatment of complicated skin and skin structure infections in adults.

Two studies recently presented at ECCMID 2016 found emerging or resistant infections and dermatologic infestations to be prevalent among refugees seeking asylum in Switzerland and the Netherlands.

A study that used electronic bottle caps to record each time a pill bottle was opened showed that patients commonly overstated their adherence to antibiotic regimens for skin and soft tissue infections.

Impavido, the only FDA-approved oral treatment for visceral, mucosal and cutaneous leishmaniasis, is now available in the United States, according to press release.

The FDA announced the approval for the first generic of Oxistat cream, 1% for treating athlete’s foot, jock itch, ringworm and tinea versicolor due to Malassezia furfur.

WASHINGTON — The therapeutic vaccine candidate GEN-003 significantly reduced genital lesions and viral shedding in patients with genital herpes simplex virus-2, according to phase 2 data presented at the American Academy of Dermatology annual meeting.

Researchers at UCLA discovered that giving patients an antibiotic improved upon drainage-only treatment for uncomplicated skin abscesses.

Global and national data comparisons found the highest prevalence of cutaneous leishmaniasis occurred in Africa and the Middle East, according to a recently published study.

Cipher Pharmaceuticals announced in a press release that Health Canada has accepted to review its new drug submission for Sitavig for treating recurrent herpes labialis in adults.

Miltefosine was well-tolerated and effectively treated complicated Old World cutaneous and mucosal leishmaniasis, making it an ideal first-line treatment option, according to findings published in Open Forum Infectious Diseases.